Therapeutic cancer vaccines have repeatedly generated immune responses without extending survival. Michael Morse, a professor of medicine at Duke University, and colleagues reported in a 2021 review that only two such vaccines had won approval in the United States or European Union. A Phase 3 trial now tests whether a vaccine can overcome those obstacles in acute myeloid leukemia (AML).
SELLAS Life Sciences reported that its Phase 3 REGAL trial of galinpepimut-S (GPS), a Wilms tumor 1 (WT1) cancer vaccine, met its primary overall survival (OS) endpoint in AML. In 126 people in second or later remission who could not receive an allogeneic stem cell transplant, median OS reached 24.0 months with GPS versus 14.7 months with best available treatment. The company reported a hazard ratio (HR) of 0.59 and a two-sided P value of 0.035.
Why did earlier cancer vaccines fail?
Earlier cancer vaccines most often failed because of weak antigens, short-peptide designs, and poorly matched trial populations, according to Morse and colleagues. A National Cancer Institute (NCI) pilot project ranked 75 cancer antigens and placed WT1, a transcription factor, first as an immunotherapy target. The telomerase peptide in the GV1001 vaccine, by contrast, ranked 23rd and failed to improve survival in pancreatic cancer.
Short peptides engaged cytotoxic T cells but not helper T cells, which limited antigen presentation. Advanced disease also brings multiple immunosuppressive mechanisms, so Morse and colleagues suggested that vaccines may work best against minimal residual disease. A maintenance trial after remission, such as REGAL, places a WT1 cancer vaccine in that low-burden setting by design.
REGAL survival sits near other AML maintenance results
REGAL's survival results for the WT1 cancer vaccine land in the range of established maintenance benchmarks; the table compares disease setting, design, and median OS across three trials.
| Trial | Disease setting | Design | Median OS, treatment versus control |
|---|---|---|---|
| REGAL (GPS) | AML in second or later remission, transplant-ineligible | Open-label, 126 patients, best available treatment control | 24.0 versus 14.7 months |
| Oral hypomethylating agent maintenance trial | AML in first remission, age 55 or older, transplant-ineligible | Double-blind, 472 patients, placebo control | 24.7 versus 14.8 months |
| First approved cancer vaccine trial | Metastatic castration-resistant prostate cancer | Randomized, placebo-controlled | 25.8 versus 21.7 months |
Andrew Wei, a hematologist at Monash University, and colleagues reported in 2020 that an oral hypomethylating agent extended survival as first-remission AML maintenance, and the U.S. Food and Drug Administration (FDA) approved it that year. REGAL enrolled about a quarter as many patients, so cross-trial comparisons call for caution. Other groups are pursuing reengineered dendritic cell vaccines that load antigen ex vivo.
WT1 cancer vaccine mechanism: CD4+ and CD8+ T cell activation
A WT1 cancer vaccine such as GPS activates CD4+ and CD8+ T cells through four WT1-derived peptides: a modified short peptide for CD8+ cells, two native long peptides for CD4+ responses, and a modified long peptide for both subsets. Single amino acid substitutions in the modified peptides raise immunogenicity while still producing T cells that recognize native WT1. SELLAS licensed GPS from Memorial Sloan Kettering Cancer Center (MSK).
A Phase 2 trial in 22 adults in first remission found that GPS induced immune responses in nine of 14 tested patients and was well tolerated. Median disease-free survival reached 16.9 months, though the single-arm design cannot isolate the vaccine's contribution. REGAL delivered GPS subcutaneously with Montanide adjuvant and sargramostim, a recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF), in biweekly priming doses, then boosters.
The REGAL Study Steering Committee said in the SELLAS press release that GPS works "[b]y training the immune system to target residual leukemia cells." Hagop Kantarjian, a professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, chairs the committee and serves as the trial's global principal investigator. SELLAS did not report REGAL's T-cell response data on November 17, so the link between the vaccine's mechanism and the survival difference remains to be shown.
What did REGAL test?
REGAL tested the WT1 cancer vaccine GPS as maintenance therapy against investigator's choice of best available treatment in an open-label, randomized trial of 126 people. Four protocol choices frame how readers should weigh the 9.3-month survival difference:
- Population: adults in second or later complete remission, with fewer than 5 percent marrow blasts, no peripheral blasts, and no extramedullary disease after salvage therapy
- Control arm: observation, a hypomethylating agent, venetoclax, or low-dose cytarabine, alone or combined
- Blinding: open-label, with no placebo comparison
- Endpoints: OS from study entry (primary); leukemia-free survival, landmark OS, safety, and measurable residual disease (secondary)
Topline REGAL data leave size and durability open
The topline result supports a survival benefit for the WT1 cancer vaccine but not yet its size or durability, because SELLAS reported one P value and no confidence interval.
Five details define the current evidence base, from event count to regulatory status.
- Events: the analysis triggered at 80 deaths among 126 randomized people
- Later therapy: SELLAS described none beyond transplant, which it called limited and balanced between arms
- Oversight: an independent data monitoring committee recommended continuing REGAL unmodified after a prespecified interim analysis at 60 deaths in January 2025, according to SELLAS
- Safety: treatment-related adverse events were predominantly grade 1 or 2, most often injection site reactions, with no new safety signals
- Designations: FDA Fast Track and Orphan Drug status for AML by 2016, according to the company
SELLAS disclosed that MSK holds institutional financial interests in the company: David Scheinberg, whose laboratory discovered GPS, and one REGAL steering committee member also hold financial interests related to SELLAS.
A WT1 cancer vaccine shows survival gain; full data pending
In the Phase 3 REGAL trial, the WT1 cancer vaccine galinpepimut-S reached a median overall survival of 24.0 months versus 14.7 months with best available treatment, a hazard ratio of 0.59, in 126 people with acute myeloid leukemia. The result is an open-label topline analysis without confidence intervals or secondary endpoints, which SELLAS said it was still evaluating. SELLAS planned to meet with the FDA and aimed to submit a Biologics License Application in the first half of 2027.
This article is based on a press release issued by SELLAS Life Sciences and was produced under Drug Discovery News' AI Editorial Guidelines.








